Only five cancers (colorectal, breast, cervical, prostate, and eligible smoker lung cancer) have screening tests proven in randomized trials to reduce cancer deaths. Our N-of-1 calendar upgrades those five screens first: colonoscopy at age 45 (or age 40 / 10 years before a first-degree relative's diagnosis, with endoscopist ADR >= 35%; NordICC per-protocol -50% mortality), baseline PSA at age 40-45 with pre-biopsy MRI (GÖTEBORG-2 halves Gleason 6 overdiagnosis; ERSPC 23-year RR 0.87), 3D mammography plus personalized MRI in extremely dense breasts (DENSE trial), primary HPV testing, targeted dermatoscopic skin exams in high-risk adults, and low-dose chest CT strictly for >= 20 pack-year smokers (never in never-smokers, where NNS is 6,162 vs. 353 and Taiwan's CT push caused a 6-fold Stage 0-I surge with zero mortality drop). Commercial whole-body MRIs ($1,500-$2,500) flag findings in 78% of healthy adults, critical/indeterminate findings in 32.1%, and actionable non-malignant findings in 14.8% (triggering ~86 follow-up workups and ~31 procedures per 1,000 scanned) for a 1.4% to 1.57% cancer yield with zero mortality data (Ahsan 2026; Martins da Fonseca 2026; Cochrane 2026). Meanwhile, the Galleri blood test has 99.5%-99.64% specificity and 60.3% PPV in PATHFINDER 2 (Nabavizadeh Nat Med 2026, n = 32,007), but its Stage I sensitivity is only 16.8%, its negative likelihood ratio is 0.61 (61% of 1-year cancers occur after a negative test), and the 142,250-adult NHS-Galleri randomized trial missed its primary endpoint of reducing Stage III-IV cancers (IRR 1.03, P = 0.63, Sasieni NEJM 2026). Neither test ever replaces Tier 1 organ screening.
TL;DR: Only five cancer screens (colon, breast, cervix, prostate, and smoker lung) are proven in clinical trials to save lives. A smart plan upgrades those five tests first before adding blood tests or full-body scans.
- Lock in your 5 core organ screens first: Start colonoscopy at age 45 (or age 40 if a close relative had colon cancer, using a doctor with a polyp detection rate of 35% or higher). Get a baseline PSA blood test at age 40 to 45 paired with a prostate MRI before any biopsy. Use 3D mammograms plus breast MRI for very dense breasts, primary HPV swabs, skin checks for high-risk adults, and low-dose lung CT only if you smoked 20+ pack-years.
- Know what Galleri catches and misses: Galleri has a very low false-alarm rate (under 0.5%), and about half to 60% of positive tests find a cancer. However, it misses 83% of Stage I cancers, 61% of cancers found within a year happened in people who tested negative, and the 142,250-person NHS-Galleri trial did not cut combined Stage III and IV cancers. Never skip a colonoscopy or mammogram because a Galleri test was normal.
- Know the trade-offs of whole-body MRI: Scanning 1,000 healthy adults flags 780 with an abnormal spot and 320 with an unclear finding while finding cancer in 14 to 16 people (about 1.5%). We save whole-body MRI for high-risk gene carriers or strong family histories and use strict radiology rules to avoid needless biopsies.
A 46-year-old trial lawyer in Rittenhouse came to me ready to spend $3,450 on a commercial whole-body MRI plus a Galleri blood test because his father had died of colon cancer at 54. At the same time, he had been putting off his first colonoscopy because he thought the blood test and MRI would cover him. We walked through why a negative Galleri test misses 83% of Stage I cancers, missed 61% of 1-year cancers in PATHFINDER 2, and spots zero colon polyps. His father's cancer at 54 meant his own colonoscopy was already two years overdue (age 40, or 10 years before his father's diagnosis). That afternoon we booked his colonoscopy with a GI doctor whose polyp detection rate is over 42%. The doctor removed two 12 mm polyps on the spot and saved him $3,450 of false reassurance.
Why do we take cancer screening forward from population guidelines without falling for wellness hype?
Population rules (USPSTF) are built for 300 million average people. Commercial ads sell $2,500 scans as a shortcut around proven care. Our personal plan upgrades your five life-saving organ screens using your family tree, genes, and quality scores. We pair every optional test with clear math so you never trade missed early cancers for needless biopsies.
Only five cancers (colon, breast, cervix, prostate, and smoker lung) have randomized trial proof that screening cuts cancer deaths (Rubin JAMA 2026). Together they cause about 30% to 35% of US cancer deaths. The other 65% to 70% (pancreas, ovary, liver, stomach, kidney, and blood cancers) have no population screening trials. That gap is why patients ask about blood tests and whole-body MRI, and why you deserve an unconflicted doctor who shares the numbers on both.
Tier 1: What does a high-precision, personal organ-specific screening calendar look like?
Before spending money on commercial blood tests or whole-body magnets, we upgrade your five core organ screens from insurance minimums to precision care:
| Organ & Target | Standard Population Guideline | Fishtown Medicine Proactive Upgrade & Evidence Nuance |
|---|---|---|
| Colorectal | Age 45-75 (USPSTF Grade B 45-49, Grade A 50-75: colonoscopy q10y or yearly FIT; COLONPREV Lancet 2025 showed 10-yr FIT non-inferiority; 2026 ACS puts blood tests second-line only). | Average risk: Start at 45. Family history (1 first-degree relative < 60 with CRC/advanced polyp, or >= 2 at any age): Start at age 40 or 10 years before the youngest relative, repeating every 5 years (if 1 relative >= 60, start at 40 on standard intervals, NCCN 2026). Require endoscopist ADR >= 35% (>= 40% men, >= 30% women), cecal reach >= 95%, and withdrawal >= 8 min (Rex AJG 2024; each +1% ADR cuts interval CRC by 3% and fatal CRC by 5%, Corley NEJM 2014; NordICC per-protocol -50% deaths, Bretthauer NEJM 2022). |
| Prostate | USPSTF Grade C shared choice aged 55-69; AUA 2026 baseline at 45-50. | Draw a baseline PSA at age 45-50 (or 40-45 for Black men, BRCA2 carriers, or strong family history). In PROBASE (Eur Urol 2024), PSA < 1.5 ng/mL at age 45 marks very low 5-year risk (< 1.0 ng/mL retest q2-4y; 1-3 ng/mL q1-2y). If PSA is high, check PSA density + pre-biopsy mpMRI (or PRISM biparametric MRI, JAMA Oncol 2026), which halves Gleason 6 overdiagnosis (GÖTEBORG-2, Hugosson NEJM 2022). The 23-year ERSPC follow-up (Roobol NEJM 2025) proved a 13% drop in prostate cancer deaths (RR 0.87, 456 invited / 12 diagnosed per death prevented). |
| Breast & Dense Breasts | Mammogram every 2 years aged 40-74 (USPSTF 2024); risk check by age 25 (ACR). | 3D mammograms (DBT) starting at 40 (~83 callbacks and 5.8 cancers found per 1,000 vs. 103-116 callbacks and 5.1-5.3 cancers with 2D; ~82% of recalls end without biopsy, including ~71% benign BI-RADS 1/2 and 11.4% BI-RADS 3, Lee BCSC 2023 / NMD 2024). Dense breasts (Category C/D) nuance: NCCN v1.2026 recommends breast MRI starting at 50 (consider from 40) for extremely dense Category D breasts (DENSE trial Bakker NEJM 2019: full-protocol MRI halved interval cancers from 5.0 to 2.5 per 1,000 ITT, and 0.8/1,000 in MRI attendees; in the UK BRAID RCT, Gilbert Lancet 2025, abbreviated MRI [17.4/1,000] and CEM [19.2/1,000] caught 4x more cancers than automated ultrasound [4.2/1,000]), while USPSTF (I statement) and ACP 2026 note mortality data are pending. We match added MRI or CEM to Category D or high-risk Category C (relative risk >= 2, Tosteson 2026). |
| Cervical & HPV | Pap q3y (21-29); primary HPV q5y preferred (30-65, WPSI / ACOG 2026). | Primary HPV testing every 5 years (ages 30-65) (with FDA-cleared self-collected vaginal HPV swabs every 3 years as an option, Holt JAMA Intern Med 2026) plus Gardasil 9 vaccine (through age 45). Catches and treats precancer (CIN) before cancer forms. |
| Skin / Melanoma | USPSTF Grade I (not enough evidence for routine checks in low-risk adults). | Why guidelines are cautious: Mass skin screening carries an estimated ~60% melanoma overdiagnosis rate (Joshi JAMA 2025) and showed no drop in deaths in Germany's national program (Hübner JAMA Derm 2026). Our rule: We focus every 6-to-12-month dermatoscopic checks on high-risk adults (past/family melanoma, atypical moles, fair skin/blistering sunburns, immune suppression, older White men, or pre-BBL/MOXI laser checks, Straub AAFP 2026), where dermoscopy cuts benign biopsies down to ~4:1. |
| Lung (Eligible Smokers Only) | Yearly LDCT for ages 50-80 with >= 20 pack-years (USPSTF: current or quit < 15y; ACS 2023 drops the years-since-quit limit, Wolf 2023). | Screen eligible >= 20 pack-year smokers (NLST -20% and NELSON -24% lung cancer deaths; Lung-RADS halves false positives). Never order screening LDCT in never-smokers: Modeling shows 6,162 average-risk never-smokers must be screened to prevent 1 death vs. 353 smokers (Xu Lancet Reg Health 2026). In Taiwan's TALENT study (Chang 2024), 96.5% of cancers found were Stage 0-I (mostly AIS/MIA), and CT promotion in Taiwanese women caused a 6-fold surge in early diagnoses with zero drop in late cancer or deaths (Gao, Wen & Welch JAMA Intern Med 2022). Instead, test home radon (fix if >= 4.0 pCi/L, EPA). |
Tier 2: How do Whole-Body MRI (Prenuvo / Ezra) and Galleri (MCED) perform in 2026 studies?
Both whole-body MRI and Galleri are optional Tier 2 layers. Neither has randomized trial proof that it cuts cancer deaths, and a normal result on either test gives far less protection than most people think (Davenport & Reeder JAMA June 2026).
1. Commercial Whole-Body Screening MRI (Prenuvo, Ezra, and Similar)
Four pooled reviews (Kwee & Kwee JMRI 2019, n = 5,373; Gibson et al., BMJ 2018, n = 27,643; Ahsan et al., JGIM 2026, n = 18,043; and Martins da Fonseca et al., European Radiology 2026, n = 9,024) show what happens when 1,000 healthy adults get a whole-body MRI:
- 780 per 1,000 (78.0%) have at least one abnormal finding flagged (Ahsan 2026).
- 320 per 1,000 (32.1%) have a serious or unclear finding (Kwee 2019; in a 2026 ONCO-RADS study by Ali et al., 42.2% had an ONCO-RADS 3 or higher spot while cancer was 0.9%).
- 150 per 1,000 (14.8%) have an actionable non-cancer finding, which triggers 86 follow-up scans or lab workups (58.2%) and 31 invasive procedures (20.8%) (Ahsan 2026).
- 14 to 16 per 1,000 (1.4% to 1.57%) are diagnosed with cancer (Ahsan 2026; Martins da Fonseca 2026), with zero randomized mortality data to show how many are life-saving catches versus harmless overdiagnosis (Chen et al., Cochrane 2026).
- The pancreatic cyst, cost, and biopsy cascade: In the largest screening MRI study to date (Wong et al., JAMA Network Open 2026, n = 21,651), 7.0% of healthy adults had incidental pancreatic cysts (rising to 20.8% at age 80 and up). Only 0.08% had cysts over 3 cm, yet about 1,500 people entered years of scan follow-up. In Germany's SHIP study, sharing whole-body MRI findings raised 2-year outpatient costs by 11.6% (Schmidt BMJ Open 2022) and raised benign biopsies by 39% (rate ratio 1.39, Richter Eur J Epidemiol 2020). At the same time, 2.8% of scans had false-negative results that missed colon, breast, and thyroid cancers (Basar Eur J Radiol 2021).
- When whole-body MRI is endorsed (NCCN 2026): NCCN recommends yearly whole-body MRI for hereditary syndromes like Li-Fraumeni (TP53), where cancer yield is about 7% (versus 1.5% in the general public, Ballinger JAMA Oncol 2017). For the general public, the American College of Preventive Medicine (Choosing Wisely), a 2026 AJR Expert Panel, and a June 2026 JAMA editorial advise against routine scans.
Longevity Medicine
A personalized longevity strategy starts with knowing your real baselines.
2. The Galleri Multi-Cancer Blood Test (PATHFINDER 2 & NHS-Galleri 2026)
Five landmark trials (CCGA3, PATHFINDER, SYMPLIFY, PATHFINDER 2, and NHS-Galleri) map how cell-free DNA methylation testing performs:
| Study & Population | Specificity | Sensitivity (All Cancers & By Stage) | Positive Predictive Value (PPV) & Origin (CSO) | Key Clinical Takeaway |
|---|---|---|---|---|
| CCGA3 (Klein Ann Oncol 2021, n = 4,077 case-control) | 99.5% | Overall: 51.5% Stage I: 16.8% (Stage II: 40.4%, Stage III: 77.0%, Stage IV: 90.1%) | Case-control (N/A) Origin (CSO): 88.7% | Misses 83.2% of Stage I cancers (and 95% of Stage II prostate cancers). |
| PATHFINDER (Schrag Lancet 2023, n = 6,662 aged >= 50) | 99.1% | 12-month episode: 29.5% | 38.0% (43.1% refined assay) Origin: 85% first / 97% top-2 | False positives took a median of 162 days of scans and procedures to clear. |
| SYMPLIFY (Nicholson Lancet Oncol 2023, n = 5,461 with symptoms) | 98.4% | Overall: 66.3% (Stage I: 24.2%; prostate: 9.1%) | 75.5% (6.7% base rate) Origin: 84.8% | Higher yield when symptoms are already present. |
| PATHFINDER 2 (Nabavizadeh Nat Med 2026, n = 32,007 aged >= 50) | 99.64% | All cancers:** 39.3% (54.9% without breast/prostate) 12 deadly cancers: **69.8% | 60.3% PPV** Origin (CSO): **91.3% | Negative Likelihood Ratio = 0.61: 61% of 1-year cancers (267 / 440) happened in people who tested negative (~5 found, ~4 false positives, ~8 missed per 1,000). |
| NHS-Galleri RCT (Sasieni NEJM Oct 2026; Neal Nat Med 2026, n = 142,250 aged 50-77, 3 rounds) | 99.50% to 99.60% | All cancers: 26.7% to 37.2% (melanoma: 2.5%) | Round 1 -> 2 -> 3 PPV: 58.0% -> 50.4% -> 45.8% Origin: 91.1%-93.6% | Missed primary goal of cutting Stage III-IV cancers in the 12 target types (IRR 1.03, 95% CI 0.92-1.14, P = 0.63; all staged cancers IRR 1.05). Fewer Stage IV cases (341 vs. 394; RR 0.86 overall, RR 0.74 Round 3) were offset by more Stage III cases (360 vs. 287). |
Metabolic & Genetic Defense: Making Your Body Hostile to Cancer
- Map family genes early: When your family tree shows breast cancer under 50, triple-negative breast cancer, ovarian or pancreatic cancer at any age, colon or uterine clustering, or several affected relatives on one side, we order medical gene testing (BRCA1/2, PALB2, ATM, CHEK2, Lynch MLH1/MSH2/MSH6/PMS2, APC, TP53). A positive variant changes your whole schedule. Lynch carriers start colonoscopies in their 20s, BRCA carriers alternate mammograms and breast MRI every 6 months, and Li-Fraumeni TP53 carriers get NCCN-endorsed whole-body MRI.
- Lower high insulin (IGF-1) and belly fat: High insulin and visceral belly fat (100 cm2 or more on DEXA) raise the risk of at least 13 cancers (colon, breast, uterine, pancreas, liver, kidney) by turning on tumor insulin and IGF-1 growth switches. Keeping fasting insulin below 6 to 8 uIU/mL, hs-CRP below 1.0 mg/L, alcohol low, and muscle mass high protects every organ at once.
Guidance from the Clinic
Key Takeaways
- Complete & Upgrade Your 5 Mortality-Proven Organ Screens First: Colonoscopy (age 45, or 40 / 10y early for family history, with endoscopist ADR >= 35%, NordICC -50% per-protocol mortality), risk-adapted PSA at 40-50 + pre-biopsy mpMRI (GÖTEBORG-2; ERSPC 23-yr RR 0.87), 3D mammography + personalized dense-breast MRI (DENSE trial), primary HPV testing (ages 30-65), high-risk dermatoscopic skin exams, and >= 20 pack-year smoker LDCT are the only screens proven to save lives.
- Know Galleri's 2026 Trial Reality (PATHFINDER 2 & NHS-Galleri): 99.5%-99.64% specificity and 45.8%-60.3% PPV, paired with 16.8% Stage I sensitivity, a 0.61 negative likelihood ratio (61% of 1-year cancers missed after a negative test), and a missed primary Stage III-IV endpoint (IRR 1.03, P = 0.63) in NHS-Galleri.
- Know Whole-Body MRI's 1,000-Person Funnel: ~320 indeterminate findings, ~86 follow-up workups, and ~31 procedures per 1,000 adults scanned for 14 to 16 cancers (1.4%-1.57%) and zero mortality proof (Cochrane 2026). Reserve for hereditary syndromes (Li-Fraumeni ~7% yield) or triage with ONCO-RADS and ACR cutoffs.
Related at Fishtown Medicine
- What the NHS-Galleri Trial Showed (And What It Means for Your Screening)
- Grail Galleri Liquid Biopsy Guide
- Boutique Whole-Body Scans & The Friday-Afternoon Incidentaloma Triage Guide
- Colorectal Cancer Screening: Colonoscopy vs. FIT, Cologuard & Shield
- PSA & Multiparametric Prostate MRI Screening
- Mammogram Callbacks (BI-RADS 0) & Dense Breasts
Scientific References
- Multi-Cancer Early Detection (CCGA3, PATHFINDER, PATHFINDER 2, NHS-Galleri): Klein EA, Richards D, Cohn A, et al. (CCGA3). Ann Oncol. 2021;32(9):1167-1177; Schrag D, Beer TM, McDonnell CH 3rd, et al. (PATHFINDER). Lancet. 2023;402(10409):1251-1260; Nabavizadeh N, McDonnell C, Kurbegov D, et al. (PATHFINDER 2). Nat Med. 2026; Sasieni P, Johnson P, Round T, et al. (NHS-Galleri Trial). N Engl J Med. 2026; and Neal RD, Dolly S, Johnson P, et al. Nat Med. 2026.
- Whole-Body MRI Meta-Analyses, Cohorts & Editorials: Kwee RM, Kwee TC. J Magn Reson Imaging. 2019;50(5):1489-1503; Ahsan MD, Frontera N, Gurram A, et al. J Gen Intern Med. 2026; Martins da Fonseca J, Trennepohl T, Pinheiro LG, et al. Eur Radiol. 2026; Wong P, Pollini T, Hernandez S, et al. JAMA Netw Open. 2026; Chen Z, Johansson M, Albarqouni L, et al. Cochrane Database Syst Rev. 2026; and Davenport MS, Reeder SB. JAMA. 2026.
- High-Precision Organ Screening (NordICC, ADR, ERSPC 23-Yr, GÖTEBORG-2, DENSE, Never-Smoker LDCT): Bretthauer M, Løberg M, Wieszczy P, et al. (NordICC). N Engl J Med. 2022;387(17):1547-1556; Corley DA, Jensen CD, Marks AR, et al. N Engl J Med. 2014;370(14):1298-1306; Roobol MJ, de Vos II, Månsson M, et al. (ERSPC 23-Year). N Engl J Med. 2025; Hugosson J, Månsson M, Wallström J, et al. (GÖTEBORG-2). N Engl J Med. 2022;387(23):2126-2137; Bakker MF, de Lange SV, Pijnappel RM, et al. (DENSE). N Engl J Med. 2019;381(21):2027-2037; and Gao W, Wen CP, Wu A, Welch HG. JAMA Intern Med. 2022;182(3):302-310.
Frequently Asked Questions
Common Questions
Ready when you are
The chat is our AI assistant, answering from our published guides. To talk it through with Dr. Ash himself, start with the intake.





